•
Dec 31, 2020
RAPT Q4 2020 Earnings Report
Reported financial results for the fourth quarter and year ended December 31, 2020.
Key Takeaways
RAPT Therapeutics reported a net loss of $12.7 million for the fourth quarter of 2020, compared to $13.2 million for the fourth quarter of 2019. The company's research and development expenses were $10.9 million, and general and administrative expenses were $3.5 million for the same period.
Achieved important advancements in clinical development for FLX475 in oncology and RPT193 in inflammatory diseases.
Reported early evidence of clinical activity for FLX475 as monotherapy and in combination with pembrolizumab.
Continued enrolling Phase 1b study of RPT193 in atopic dermatitis.
Well positioned for key data readouts for both RPT193 and FLX475.